Member Info for GG1111

Ricky ..I would say there is zero chance of this happening..

Moz.. I understand your thinking but it is actually almost certain that any company that might want to acquire Open Orphan would NOT be buying cheap shares prior to a bid .
The reality is that any such company/companies must have signed an NDA in order to be privy to up to the minute price sensitive information as part of their due diligence .
Consequently takeover panel rules prohibit trading in the shares and the panel watch transactions very closely in situations like this to ensure existing shareholders are not disadvantaged.
Hope that makes sense .

ORPH is unborrowable ..just to stop the shorting rumours

No problem Elrico..All good

Thanks Moni no offence taken ..
Of course a share buy back is always earnings per share enhancing IN THE STRICTEST SENSE..it cannot not be .
Let’s just leave it at that .x

Moni/ and Fellow Posters ..I do think I know how share buy backs work ! Do you ?
Do you know what eps dilutive means and how to do the calculation ?
I'm not minded to give you a maths lesson but it's pretty simple stuff . A share buy back of open orphan shares at todays price or higher would horribly dilute earnings per share and therefore a non starter .
Dividend ..yes please , share buy back .. dream on .

Guys all good debate ..I agree let Cathal crack on ..

Well I would say For 2022 Fincrap are wrong …but either way a share buy back would be highly dilutive

Moniman..do you not think a share buy back would be out of the question as we raised money at 11p so buying shares back at 20p would be earnings dilutive ..especially when we have a forward PE of more than 12..it would destroy shareholder value
Just a thought.

Thank you Elric for your reply.

Hi Elrico ,
Can I ask what time you posted the interview today on You Tube ..

£10,136,899 to be precise

Think the date is 19th April

That all sounds familiar..is that not what Flu .V does ..
It is also designed to minimise the impact of the influenza virus by reducing symptoms, potentially relegating influenza to a much milder disease by stimulating an immune response mediated through T-cells and B-cells that recognise infected cells and destroy them, in contrast to seasonal influenza vaccines that prevent infection through antibody protection against external proteins.

Two Phase IIb studies have achieved primary endpoints:

Position terminated 7/Sept 21

I thought Stoloff had been shown the door

Can’t see any reason why there wouldn’t be a bidding war ..and all before Xmas …how exciting..

FFS

Synergy and cross pollination will have to be paid for ,and I don’t think Cathal can even spell discount

Think again Moniman

Poolbeg is named after the Poolbeg power station ..
Hence the Poolbeg logo ..I think it’s a great name ..